• Explore /
  • Poster
  • / Healthcare resource utilization (HCRU), costs, and mortality in relation to select immune-related adverse events (irAEs) and line of therapy (LOT) in patients (pts) with advanced or metastatic urothelial cancer (UC) treated with immune checkpoint inhibitor (ICI) monotherapy.

Healthcare resource utilization (HCRU), costs, and mortality in relation to select immune-related adverse events (irAEs) and line of therapy (LOT) in patients (pts) with advanced or metastatic urothelial cancer (UC) treated with immune checkpoint inhibitor (ICI) monotherapy.

Abstract Poster

Authors

Saby George

Saby George

Roswell Park Comprehensive Cancer Center, Buffalo, NY

Saby George , Ying Zheng , Elizabeth Bell , Nicole Engel-Nitz , John C White , Lincy S. Lal , Mo Yang , Geeta Devgan , Jodi Smith , Ruth Kim , Frank Xiaoqing Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 427)

DOI

10.1200/JCO.2021.39.6_suppl.427

Abstract #

427

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jarushka Naidoo

First Author: Gregory E. Sanda

First Author: Pier Vitale Nuzzo

First Author: Haojie Li